Tocqueville Asset Management L.P. Sells 106,149 Shares of Smith & Nephew plc (NYSE:SNN)

Tocqueville Asset Management L.P. cut its position in Smith & Nephew plc (NYSE:SNN - Free Report) by 44.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 131,272 shares of the medical equipment provider's stock after selling 106,149 shares during the period. Tocqueville Asset Management L.P.'s holdings in Smith & Nephew were worth $3,227,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Signaturefd LLC raised its holdings in Smith & Nephew by 4.3% in the fourth quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider's stock worth $388,000 after purchasing an additional 653 shares during the period. Corient Private Wealth LLC raised its holdings in shares of Smith & Nephew by 6.8% during the fourth quarter. Corient Private Wealth LLC now owns 34,640 shares of the medical equipment provider's stock worth $851,000 after acquiring an additional 2,197 shares during the period. Natixis Advisors LLC raised its holdings in shares of Smith & Nephew by 59.9% during the fourth quarter. Natixis Advisors LLC now owns 125,789 shares of the medical equipment provider's stock worth $3,092,000 after acquiring an additional 47,116 shares during the period. Brandes Investment Partners LP raised its holdings in shares of Smith & Nephew by 11.4% during the fourth quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider's stock worth $33,504,000 after acquiring an additional 138,994 shares during the period. Finally, River Road Asset Management LLC raised its holdings in shares of Smith & Nephew by 64.0% during the fourth quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider's stock worth $49,947,000 after acquiring an additional 792,829 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

SNN has been the topic of a number of research analyst reports. UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Canaccord Genuity Group restated a "hold" rating and set a $27.00 price objective on shares of Smith & Nephew in a report on Monday, March 17th. Finally, StockNews.com upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Smith & Nephew presently has a consensus rating of "Hold" and an average price target of $27.00.

Smith & Nephew Stock Down 1.3 %

Smith & Nephew stock traded down $0.38 during mid-day trading on Friday, reaching $28.08. The company's stock had a trading volume of 443,227 shares, compared to its average volume of 817,297. The company has a market capitalization of $12.27 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. Smith & Nephew plc has a 12 month low of $23.65 and a 12 month high of $31.72. The business's 50 day simple moving average is $26.77 and its 200 day simple moving average is $27.09. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be given a $0.447 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a yield of 2.5%. This is an increase from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's dividend payout ratio (DPR) is 41.20%.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.